Throughout this report, results are stated before exceptional items and goodwill amortisation. Trading profit represents operating profit before exceptional items and goodwill amortisation and before R&D. Growth rates are at constant exchange unless otherwise indicated.

	12 months to 31 Dec 2002		12 months to 31 Dec 2001 restated*		Growth at constant exchange rate		Growth at actual exchange rate
	£m		£m		%		%
Sales	1,618.2		1,602.5		7	#	1
Amersham Health	947.7		922.0		8		3
Amersham Biosciences	670.5		680.5		6	#	(1	)
Trading profit	494.0		466.3		7		6
Research and development	(184.2	)	(173.8	)	6		6
Operating profit	309.8		292.5		7		6
Profit before tax	300.3		279.4		8		8
Earnings per share	29.9	p	26.6	p	15		12
Statutory earnings per share1	26.1	p	33.2	p			(21	)
Dividend per share	7.8	p	7.1	p			10

*Restated for the introduction of Financial Reporting Standard 19 ‘Deferred taxation’
^#Comparable growth excluding disposed businesses
¹After exceptional items and goodwill amortisation

North America		Europe		Japan*		Rest of World
Sales £799 million, up 8% Employees: 2,900		Sales £428 million, up 8% Employees: 6,200		Sales £264 million, up 1% Employees: 250		Sales £127 million, up 3% Employees: 700

*Includes share of sales in joint venture, Nihon Medi-Physics (NMP), but does not include NMP employees